3D Printing of Pharmaceuticals: Quality Assurance Considerations and Regulatory Challenges
Anuj S. More¹*, Amol R. Pawar1,2, Pankaj S. Patil¹, Vikas V. Patil¹
1Department of Quality Assurance,
Kisan Vidya Prasarak Sansthas Institute of Pharmaceutical Education, Boradi 425428, India.
2 Research Scholar, Sankalchand Patel University, Visnagar 384315, Gujarat, India.
*Corresponding Author E-mail: anujmore39@gmail.com
ABSTRACT:
The conceptual roots of 3D printing can be traced to the development of topographical modelling and photo-sculpture techniques in the late eighteenth century1. In 1860, the French artist François Willème introduced a photo-sculpture technique in which the subject to be reproduced was placed inside a circular chamber surrounded by 24 evenly spaced cameras2. The resulting photographs were used to trace 24 corresponding profiles, which were then cut from wood using a cutter linked to a pantograph, gradually shaping the desired form2. Building on this concept of layered reproduction, Blanther was granted a patent for a topographical relief map in 18921. This approach, known as the cut-and-stack (or stack-and-cut) method, involved stacking individually cut layers to create a die set capable of pressing paper into a three-dimensional relief structure3,4. Nearly a century later, in 1968, Swainson introduced a technique that used a focused laser beam to selectively harden photosensitive polymers, a process termed photochemical machining5. a comparable approach was independently pursued by Battelle Laboratories around the same period6,7. In 1971, Ciraud proposed an alternative strategy that employed laser, electron, or plasma beams as heat sources to bring partially melted particles into a molten state, enabling their fusion into solid structures8.
The modern era of 3D printing is generally considered to have begun with Charles “Chuck” Hull’s invention of stereolithography and his founding of 3D Systems in the early 1980s, followed by the commercial introduction of stereolithography in 1986—widely regarded as the first true 3D printer1,4. A few years later, in 1988, Scott Crump of Stratasys introduced fused deposition modelling (FDM), another foundational additive manufacturing technology9. Around the same period, two further techniques emerged: laminated object manufacturing (LOM), developed by Helisys, and solid ground curing (SGC), introduced by Cubital10. A timeline summarizing these key milestones in the evolution of 3D printing is presented in Fig. 1.
The application of 3D printing within healthcare continues to expand rapidly. Numerous commercial applications now exist across medical and pharmaceutical settings, and the global 3D printing market—currently valued at more than USD 700 million—is projected to grow substantially, potentially reaching USD 8.9 billion, of which an estimated USD 1.9 billion is expected to be attributable to medical applications. Within pharmaceutics, this technology has given rise to “printlets” (3D-printed solid oral dosage forms), which allow formulations to be tailored to individual patient requirements with respect to appearance, shape, size, dose, active pharmaceutical ingredient(s), route of administration, and drug release rate. SPRITAM®, developed by Aprecia using its proprietary ZipDose® technology, represents the first FDA-approved 3D-printed pharmaceutical product. The ZipDose® platform permits loading of up to 1000 mg of drug substance within a single dose. Its first layer comprises the active ingredient together with the excipients required to form the tablet matrix, after which a binder liquid is applied to promote seamless integration and aggregation of successive layers11. The resulting high-dose Spritam® tablet is designed to disintegrate rapidly upon contact with a small volume of liquid. The underlying technology originated at the Massachusetts Institute of Technology and was subsequently commercialized by Aprecia12.
Figure 1: Evolution of 3D Printing Technologies: Historical Timeline
Fig. 2: Illustration of inkjet-based 3D printing technology.
Inkjet printing is broadly classified into two categories based on the mechanism of drop generation and deposition: continuous inkjet (CIJ) and drop-on-demand (DOD) printing. In CIJ systems, ink flows continuously through an orifice, with piezoelectric transducers positioned near the nozzle and an applied electrostatic field guiding the deposition of charged droplets onto the substrate5. DOD printing, by contrast, generates droplets only when required, in response to a triggering signal, thereby consuming less ink than continuous systems. Two principal print-head designs are used in DOD printing: piezoelectric print heads4,7 and thermal print heads3,6. Piezoelectric heads are generally preferred for drug delivery applications because they operate effectively at room temperature and are compatible with a broad range of biocompatible, low-volatility solvents. Thermal print heads, in contrast, require elevated temperatures that can compromise the stability of thermolabile active ingredients8. DOD inkjet printing can be further subdivided into drop-on-liquid and drop-on-solid modalities. In drop-on-liquid printing—also referred to as drop-on-drop deposition—successive liquid droplets are deposited under a heated air stream, allowing solvent evaporation and the progressive construction of a layered structure. This approach is particularly suited to fabricating microstructures with high drug-loading capacity for targeted drug delivery9. Conventional microstructure fabrication methods, such as spray drying, phase separation, and solvent evaporation, are often limited by low drug loading, inconsistent particle shape, and broad size distribution; the drop-on-drop inkjet approach offers a means of overcoming these constraints10.
As depicted in Fig. 1, drop-on-solid printing—also termed drop-on-powder deposition—involves depositing liquid droplets onto the surface of a powder bed, fusing the powder particles to form a solid structure. Following drying and complete evaporation of residual solvent, the deposited droplets can either solidify independently or act as a binder that consolidates the surrounding powder particles11. This drop-on-solid approach enables the fabrication of controlled drug delivery systems for a wide range of pharmaceutical actives, and it was the method used to produce Spritam®, the first FDA-approved 3D-printed pharmaceutical product12. Because the active pharmaceutical ingredient (API) can be incorporated into either the binder ink or the powder bed, this technique is capable of achieving high drug loading. Various polymeric materials that modulate drug release rate, such as ethyl cellulose and Eudragit®, can serve as binder inks for the design of targeted or controlled-release delivery systems13. The use of differently coloured inks also allows for product colour customization, which may enhance patient acceptability, particularly among paediatric and elderly populations. Limitations of this technique include product brittleness and friability arising from high porosity, stability concerns associated with the use of organic solvents, and the risk of nozzle blockage during ink preparation5,14.
Fig. 3: Illustration of extrusion-based 3D printing technique.
(a) Pressure-assisted microsyringe (PAM) printing technique
(b) Fused deposition modeling (FDM) printing technique.
The PAM technique, also referred to as semi-solid extrusion (SSE), employs pastes or semi-solid materials as the printing medium. A typical PAM-based 3D printer comprises a syringe extruder system, a compressor, and a computer running 3D design and slicing software. A metal or plastic syringe pre-loaded with the semi-solid paste is fitted into the extruder, which is connected to a pressure-controlled air pump; the applied pressure drives extrusion of the material through nozzles of varying size and shape. The printer head moves horizontally to deposit the first layer, after which the build stage descends to allow deposition of subsequent layers, and this cycle is repeated until the complete three-dimensional structure is formed.
The three-dimensional object is designed and sliced using computer-aided design (CAD) and slicer software, generating an STL file from which G-code is produced to configure the printing parameters. A supplementary heating element may be incorporated into the extruder and build stage to melt or soften the printing material, or to accelerate solvent evaporation during layer formation.
Achieving reliable prints with PAM technology requires careful optimization of several parameters. The consistency of the paste must be tightly controlled and free of coarse particles to prevent nozzle blockage. Because the paste is typically prepared using organic or inorganic solvents, solvent selection is critical: excessively volatile solvents may cause premature evaporation and nozzle obstruction, whereas insufficiently volatile solvents can prolong the drying time of deposited layers.
Material viscosity and consistency directly influence key printing parameters, including extrusion pressure, print speed, and nozzle geometry. Low-viscosity materials can typically be extruded at lower pressures through smaller nozzles, whereas more viscous formulations require higher pressures and larger nozzle diameters. Layer thickness and dimensions are governed by the extrusion rate, nozzle size, and applied pressure, and these layer characteristics must be established before the overall object geometry can be designed. Printing speed is likewise constrained by material viscosity: highly viscous materials cannot be printed at high speeds, since insufficient material would be extruded to form the intended layer, while low-viscosity or rapidly extruding materials cannot be printed slowly without distorting layer geometry through dragging or bloating16.
A key advantage of PAM-based 3D printing is its compatibility with heat-sensitive materials, as the process can be conducted at room temperature using a wide range of pharmaceutical-grade excipients, while also achieving high drug loading. Its principal drawbacks include the use of organic solvents, which may compromise API stability, and the drying time required for printed layers. The printing resolution achievable with this method is comparatively lower than that of other techniques, being constrained largely by layer formation and nozzle dimensions17.
FDM represents another widely investigated extrusion-based technique for customized drug delivery. In this process, material supplied in filament form is melted and extruded through a heated nozzle, solidifying rapidly to form a single layer; the build stage is then lowered, and the cycle is repeated to construct the complete three-dimensional object18. Filament preparation constitutes the primary prerequisite for FDM-based printing, and converting pharmaceutical-grade materials into printable filaments remains the principal technical challenge in applying this method to dosage form manufacture. Filaments are typically produced by melting and extruding a polymeric mixture through a heated orifice using a hot-melt extruder (HME). The API may either be incorporated into the polymer before hot-melt extrusion, or the resulting filament may subsequently be soaked in an API-containing solution. The prepared filament is then mounted on the print head and extruded layer-by-layer through a heated nozzle to construct the desired geometry. Precise control of printing temperature is essential for consistent, uninterrupted extrusion, and the filament must possess sufficient mechanical and thermal resilience to withstand the stresses encountered during printing. The nozzle temperature must exceed the filament’s melting point to ensure smooth, unobstructed extrusion, while the build-stage temperature must remain below this melting point to permit re-solidification of the deposited material. The brittleness, rigidity, and plasticity of the filament have a direct bearing on both the printing process and the quality of the resulting product19.
The principal advantage of FDM printing, across all applications, lies in its relatively low cost. In drug delivery contexts, additional benefits include the absence of organic solvents, elimination of post-processing steps, superior mechanical strength, and improved printing resolution relative to PAM-based systems. Because the resulting printed materials tend to resist disintegration, FDM-printed formulations typically exhibit slower drug release; however, this release profile can be modulated by adjusting the infill pattern and infill percentage20. The principal limitation of FDM is the high processing temperature required during filament production and extrusion, which renders the technique unsuitable for thermolabile APIs and low-melting-point polymers21.
In SLA, the laser is directed onto the uppermost layer of a photosensitive polymeric liquid resin, selectively polymerizing and solidifying a defined region to form a solid layer. The resin reservoir is then lowered to allow the laser to form the subsequent layer, progressively building the three-dimensional structure22. SLA has also been applied to fabricate microstructures for transdermal drug delivery and drug-loaded hydrogels.
The principal barrier to broader adoption of SLA in dosage-form manufacturing is the limited availability of FDA-approved photopolymeric liquid resins. In addition, the inherent instability of photosensitive resins, together with the potential leaching of residual photoinitiators and unreacted monomers from the printed structure, raises concerns regarding cytotoxicity23.
The principal advantage of SLA lies in its exceptionally high printing resolution—up to 0.2 µm—compared with the 50–200 µm resolution typically achievable using other 3D printing techniques. The resolution and layer thickness of the printed object are strongly influenced by the intensity and exposure time of the laser beam.
SLS, a powder-based solidification technique, forms each layer by using a laser beam to sinter a powder bed at a temperature below the polymer’s melting point, thereby fusing the particles into a solid structure. After each layer is completed, the build stage is lowered, and a fresh layer of powder is drawn from the feed chamber, exposed to the laser, and fused to extend the three-dimensional structure. The resulting layer thickness and print resolution are governed by the laser’s focus, intensity, and scanning speed, as well as the particle size of the powder blend24.
The principal advantages of SLS include its high resolution and single-step processing, which eliminates the need for organic solvents or post-print drying. Its main limitations include the potential for API degradation due to the melting involved in laser sintering, the restricted range of suitable photosensitive polymers, and the inability to fabricate hollow structures25.
Within the pharmaceutical industry, 3D printing holds the potential to shift tablet manufacturing away from centralized production facilities toward decentralized settings such as clinics, community pharmacies, or even patients’ homes—supporting a broader transition from mass production toward mass personalization and customization. Decentralized pharmaceutical manufacturing offers three principal advantages. First, it can reduce the time and cost associated with drug storage and distribution.
The prospect of fabricating pharmaceutical products tailored specifically to individual patients is especially compelling. Such personalization could enable customization of drug dosage, co-administration of multiple medications within a single dosage form, exclusion of excipients associated with patient intolerances (such as lactose or sucrose), and modification of flavour or ease of administration. Patient-tailored products may hold particular value for paediatric and geriatric populations, individuals with atypical drug metabolism, and patients on complex polypharmacy regimens where drug–drug interactions are a concern. The appeal of 3D printing in personalized medicine is further reinforced by potential benefits in sustainability, patentability, and manufacturing cost reduction, with treatment personalization itself identified as a potential means of reducing overall healthcare expenditure. Furthermore, the minimal footprint required for a 3D printing facility, combined with the feasibility of real-time, on-demand production, could reduce or eliminate the need for extensive storage infrastructure and long-term stability testing of finished products. This technology has the potential to reshape clinical practice within hospitals and compounding pharmacies, particularly in the context of clinical trials and the treatment of small patient populations, such as those affected by rare diseases.
Beyond personalization, 3D printing could enable more effective achievement of specific release targets—such as controlled release—that are currently difficult to attain through conventional compounding. By substantially streamlining downstream manufacturing steps, 3D printing could facilitate continuous manufacturing, a process of considerable current interest for industrial-scale pharmaceutical production26. Notably, because multiple printers can operate simultaneously, or next-generation systems can be designed with multiple print sources, 3D printing is readily adaptable to both small- and large-scale manufacturing.
Size restrictions. A further limitation of 3D printing technology is the constraint on achievable object size; despite ongoing technological advances, fabrication of very large structures remains impractical.
Raw material limitations. At present, approximately 100 raw materials are available for use in pharmaceutical 3D printing—a comparatively narrow selection relative to the broader range of materials employed in conventional pharmaceutical manufacturing.
1. FDM (or HME-FDM) formulations typically incorporate a thermoplastic polymer, a disintegrant, and a plasticizer (Banerjee, 2023).
2. SSE formulations commonly include a water-insoluble polymer functioning as a release modifier and/or disintegrant, a water-soluble polymer serving as a matrix-forming agent and/or disintegrant, and a solvent (Banerjee, 2023).
3. Direct powder extrusion (DPE) formulations generally consist of (i) a polymer and (ii) optional excipients, such as a plasticizer or disintegrant, included to improve printability and powder flow (Aguilar-de-Leyva et al., 2024).
Table 1: Raw materials used in FDM, SSE, and DPE.
|
Excipient category |
Representative examples |
Concentration range |
|
Polymers |
Alcohol-derived polymers, particularly polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), and their derivatives; cellulose-derived polymers, including ethylcellulose, hydroxypropyl cellulose, and hydroxypropylmethylcellulose; acrylic derivatives marketed as Eudragit® E PO, comprising poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) in a 1:2:1 ratio |
FDM: 45–99% (predominantly ethylcellulose, Eudragit®, polycaprolactone, polylactic acid, polyvinyl alcohol, and Soluplus® [a polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer]) (Azad et al., 2020). SSE: 2–99% (predominantly crosslinked polyacrylic acid polymers, polyvinylpyrrolidone, hydroxypropyl(methyl)cellulose, and polyethylene glycol) (Azad et al., 2020). DPE: 10–99% (most commonly polyvinylpyrrolidone, hydroxypropyl(methyl)cellulose, ethylcellulose, Eudragit®, polyethylene glycol, and crosslinked polyacrylic acid polymers) (Aguilar-de-Leyva et al., 2024) |
|
Plasticizers |
Triethyl citrate, sorbitol, mannitol |
Excipient type and concentration vary considerably depending on the printing method, formulation, and drug loading; selection is largely guided by empirical, trial-and-error optimization. |
|
Diluents |
Sorbitol, starch, mannitol, microcrystalline cellulose |
— |
|
Lubricants |
Magnesium stearate |
— |
|
Disintegrants |
Sodium starch glycolate |
— |
|
Solvents (SSE only) |
Water, ethanol |
— |
Several international regulatory authorities—including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China’s National Medical Products Administration (NMPA)—have played an active role in the regulation and approval of 3D-printed medical devices. Two notable regulatory milestones include the first FDA-approved 3D-printed cranial implant (the OsteoFab® Patient-Specific Cranial Device, developed by Oxford Performance Materials [USA], which received FDA 510(k) clearance and CE marking in January 2016) and the first 3D-printed titanium-based spinal device (the Cascadia™ Lateral Interbody System, developed by K2M Group Holdings, later acquired by Stryker in 2018). According to FDA data (Fig. 6)39, numerous 3D printing companies have since obtained 510(k) clearance for their 3D-printed medical devices, and subsequent studies have documented the successful integration of such devices within the human body.40–43
Figure 6 legend. (a) FDA-approved 3D-printed medical device timeline, 2010–2020. (b) Detailed breakdown of device types cleared annually between 2016 and 2020. (c) Concentric pie chart depicting the materials and printing technologies employed. (d) Concentric pie chart illustrating patient specificity and device type. The dataset shown includes only 3D-printed medical devices cleared through the FDA’s 510(k) pathway based on substantial equivalence; products cleared through alternative regulatory pathways are not represented. Reproduced with permission from ref.39
3D printing represents a paradigm shift in pharmaceutical manufacturing, enabling a transition from conventional mass production toward personalized, patient-centric drug therapy. Its capacity to fabricate dosage forms with customized drug doses, complex internal architectures, and controlled release profiles offers substantial clinical and commercial value, particularly for paediatric, geriatric, and polypharmacy patient populations. Inkjet-based, extrusion-based, and laser-based printing technologies each present distinct advantages and limitations, underscoring the importance of carefully selecting appropriate materials, processes, and printing parameters to ensure both product quality and therapeutic performance.
From a quality assurance standpoint, the inherent variability of additive manufacturing introduces new challenges related to raw material control, process reproducibility, in-process monitoring, and final product testing. The lack of standardized pharmaceutical-grade printing materials, coupled with continued reliance on empirical formulation development, further complicates quality management in this field. Although regulatory agencies have made meaningful progress in approving 3D-printed medical devices, regulatory pathways specific to 3D-printed pharmaceutical products remain limited and insufficiently defined. Issues such as decentralized manufacturing, protection of intellectual property, validation of digital design files, and real-time release testing will require regulatory frameworks that are simultaneously flexible and robust.
In summary, while 3D printing holds considerable promise to transform drug development and delivery, its full integration into pharmaceutical practice will depend on continued advances in material science, the establishment of standardized quality assurance protocols, and the development of clear, harmonized regulatory guidelines. Sustained collaboration among researchers, industry stakeholders, and regulatory authorities will be essential to translate this promising technology from experimental application into routine clinical and commercial use.
1. Willème, F. (1860). Photosculpture. French Patent No. 43,822 (granted in the US in 1864 as Photographing Sculpture).
2. Blanther, J.E. (1892). Manufacture of Contour Relief Maps. U.S. Patent No. 473,901.
3. Scoutaris, N., Alexander, M.R., Gellert, P.R., Roberts, C.J. Inkjet printing as a novel medicine formulation technique. J Control Rel. 2011; 156(2): 179–185.
4. Lorber, B., Hsiao, W.-K., Hutchings, I.M., Martin, K.R. Adult rat retinal ganglion cells and glia can be printed by piezoelectric inkjet printing. Biofabrication. 2013; 6(1): 15001.
5. Kolakovic, R., Viitala, T., Ihalainen, P., Genina, N., Peltonen, J., Sandler, N. Printing technologies in fabrication of drug delivery systems. Expert Opin Drug Deliv. 2013; 10(12): 1711–1723.
6. Buanz, A.B.M., Saunders, M.H., Basit, A.W., Gaisford, S. Preparation of personalized-dose salbutamol sulphate oral films with thermal ink-jet printing. Pharm Res. 2011; 28(10): 2386–2392.
7. Boehm, R.D., Daniels, J., Stafslien, S., Nasir, A., Lefebvre, J., Narayan, R.J. Polyglycolic acid microneedles modified with inkjet-deposited antifungal coatings. Biointerphases. 2015; 10(1): 11004.
8. Acosta-Vélez, G.F., Wu, B.M. 3D Pharming: Direct Printing of Personalized Pharmaceutical Tablets.
9. Deiner, L.J., Farjami, E. Diffuse reflectance infrared spectroscopic identification of dispersant/particle bonding mechanisms in functional inks. JoVE. 2015; 99: e52744.
10. Champion, J.A., Katare, Y.K., Mitragotri, S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release. 2007; 121(1–2): 3–9.
11. Katstra, W.E., Palazzolo, R.D., Rowe, C.W., Giritlioglu, B., Teung, P., Cima, M.J. Oral dosage forms fabricated by Three-Dimensional Printing™. J Control Release. 2000; 66(1): 1–9.
12. “ZipDose Technology | Spritam | Aprecia” 2018. https://www.aprecia.com/technology/zipdose.
13. Yu, D.G., Yang, X.L., Huang, W.D., Liu, J., Wang, Y.G., Xu, H. Tablets with material gradients fabricated by three-dimensional printing. J Pharm Sci. 2007; 96(9): 2446–2456.
14. Yu, D.-G., Branford-White, C., Yang, Y.-C., Zhu, L.-M., Welbeck, E.W., Yang, X.-L. A novel fast-disintegrating tablet fabricated by three-dimensional printing. Drug Dev Ind Pharm. 2009; 35(12): 1530–1536.
15. Azad, M.A., Olawuni, D., Kimbell, G., Badruddoza, A.Z.M., Hossain, M., Sultana, T. Polymers for extrusion-based 3D printing of pharmaceuticals: a holistic material–process perspective. Pharmaceutics. 2020; 12(2): 124.
16. Algahtani, M.S., Mohammed, A.A., Ahmad, J., Saleh, E. Development of a 3D printed coating shell to control the drug release of encapsulated immediate-release tablets. Polymers. 2020; 12(6): 1395.
17. Algahtani, M.S., Mohammed, A.A., Ahmad, J. Extrusion-based 3D printing for pharmaceuticals: contemporary research and applications. Curr Pharm Des. 2018; 24(42): 4991–5008.
18. Chia, H.N., Wu, B.M. Recent advances in 3D printing of biomaterials. J Biol Eng. 2015; 9(1): 1–14.
19. Korte, C., Quodbach, J. Formulation development and process analysis of drug-loaded filaments manufactured via hot-melt extrusion for 3D-printing of medicines. Pharm Dev Technol. 2018; 23(10): 1117–1127.
20. Pietrzak, K., Isreb, A., Alhnan, M.A. A flexible-dose dispenser for immediate and extended-release 3D printed tablets. Eur J Pharm Biopharm. 2015; 96 : 380–387.
21. Alhijjaj, M., Belton, P., Qi, S. An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing. Eur J Pharm Biopharm. 2016; 108: 111–125.
22. Hull, C.W., inventor; UVP, Inc., assignee. Apparatus for production of three-dimensional objects by stereolithography. United States Patent US 4,575,330 (1986).
23. Wang, J., Goyanes, A., Gaisford, S., Basit, A.W. Stereolithographic (SLA) 3D printing of oral modified-release dosage forms. Int J Pharm. 2016; 503(1–2): 207–212.
24. Olakanmi, E.O., Cochrane, R.F., Dalgarno, K.W. A review on selective laser sintering/melting (SLS/SLM) of aluminium alloy powders: processing, microstructure, and properties. Prog Mater Sci. 2015; 74: 401–477.
25. Fina, F., Goyanes, A., Gaisford, S., Basit, A.W. Selective laser sintering (SLS) 3D printing of medicines. Int J Pharm. 2017; 529(1–2): 285–293.
26. Rengier, F., Mehndiratta, A., von Tengg-Kobligk, H., Zechmann, C.M., Unterhinninghofen, R., Kauczor, H.U., Giesel, F.L. 3D printing based on imaging data: review of medical applications. Int J Comput Assist Radiol Surg. 2010; 5: 335–341.
27. Martelli, N., Serrano, C., Van Den Brink, H., Pineau, J., Prognon, P., Borget, I., El Batti, S. Advantages and disadvantages of 3-dimensional printing in surgery: a systematic review. Surgery. 2016; 159: 1485–1500.
28. Leong, K.F., Cheah, C.M., Chua, C.K. Solid freeform fabrication of three-dimensional scaffolds for engineering replacement tissues and organs. Biomaterials. 2003; 24: 2363–2378.
29. Lam, C.X.F., Mo, X.M., Teoh, S.H., Hutmacher, D.W. Scaffold development using 3D printing with a starch-based polymer. Mater Sci Eng C. 2002; 20: 49–56.
30. Hutmacher, D.W., Sittinger, M., Risbud, M.V. Scaffold-based tissue engineering: rationale for computer-aided design and solid free-form fabrication systems. Trends Biotechnol. 2004; 22: 354–362.
31. Wu, C., Luo, Y., Cuniberti, G., Xiao, Y., Gelinsky, M. Three-dimensional printing of hierarchical and tough mesoporous bioactive glass scaffolds with a controllable pore architecture, excellent mechanical strength and mineralization ability. Acta Biomater. 2011; 7: 2644–2650.
32. Korpela, J., Kokkari, A., Korhonen, H., Malin, M., Närhi, T., Seppälä, J. Biodegradable and bioactive porous scaffold structures prepared using fused deposition modeling. J Biomed Mater Res B Appl Biomater. 2013; 101: 610–619.
33. Alhnan, M.A., Okwuosa, T.C., Sadia, M., Wan, K.W., Ahmed, W., Arafat, B. Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. Pharm Res. 2016; 33: 1817–1832.
34. Norman, J., Madurawe, R.D., Moore, C.M.V., Khan, M.A., Khairuzzamana, A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Deliv Rev. 2017; 108: 39–50.
35. Prasad, L.K., Smyth, H. 3D Printing technologies for drug delivery: a review. Drug Dev Ind Pharm. 2015; 13: 1–13.
36. Jonathan, G., Karim, A. 3D printing in pharmaceutics: a new tool for designing customized drug delivery systems. Int J Pharm. 2016; 499: 376–394.
37. Sandler, N., Preis, M. Printed drug-delivery systems for improved patient treatment. Trends Pharmacol Sci. 2016; 37: 1070–1080.
38. Preis, M., Öblom, H. 3D-printed drugs for children – are we ready yet? AAPS PharmSciTech. 2017; 18: 303–308.
39. Fogarasi, M., Snodderly, K.L., Di Prima, M.A. A survey of additive manufacturing trends for FDA-cleared medical devices. Nat Rev Bioeng. 2023; 1: 687–689.
40. Zopf, D.A., Hollister, S.J., Nelson, M.E., Ohye, R.G., Green, G.E. Bioresorbable airway splint created with a three-dimensional printer. N Engl J Med. 2013; 368(21): 2043–2045.
41. Morrison, R.J., Hollister, S.J., Niedner, M.F., Mahani, M.G., Park, A.H., Mehta, D.K., et al. Mitigation of tracheobronchomalacia with 3D-printed personalized medical devices in pediatric patients. Sci Transl Med. 2015; 7(285): 285ra64.
42. Dzian, A., Živcák, J., Penciak, R., Hudák, R. Implantation of a 3D-printed titanium sternum in a patient with a sternal tumor. World J Surg Oncol. 2018; 16(1): 7.
43. Cruz, R.L.J., Ross, M.T., Powell, S.K., Woodruff, M.A. Advancements in soft-tissue prosthetics part A: the art of imitating life. Front Bioeng Biotechnol. 2020; 8: 121.
|
Received on 03.07.2026 Revised on 29.07.2026 Accepted on 19.08.2026 Published on 12.09.2026 Available online from September 19, 2026 Asian J. Research Chem.2026; 19(5):499-506. DOI: 10.52711/0974-4150.2026.00072 ©A and V Publications All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License. |
|